This Insulet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded BAER, NYT, CRK, PODD and SMMT, lowering price targets for four and adopting more cautious outlooks.
Follow the latest Summit Therapeutics Inc. (SMMT) news and market headlines alongside the live SMMT price. Stay informed on what's moving SMMT.
Analysts downgraded BAER, NYT, CRK, PODD and SMMT, lowering price targets for four and adopting more cautious outlooks.
Bernstein analyst Jeffrey Walch downgrades Summit Therapeutics (NASDAQ:SMMT) from Market Perform to Underperform and lowers the price target from $11.9 to $8.3.
The study, HARMONi-10, will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following
Salesforce, ServiceNow and Intuit drag software lower ahead of Anthropic's IPO. Treasury yields slip, and Nvidia reports after the bell.
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $43 to $42.
Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and lowers the price target from $20 to $18.
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Evercore ISI Group analyst Cory Kasimov maintains Summit Therapeutics (NASDAQ:SMMT) with a Outperform and lowers the price target from $34 to $33.
U.S. stock futures fell as Aclaris plunged 21% after its dermatitis trial failed; Summit and other stocks also dropped in premarket trading.
Summit Therapeutics' shares plunged over 20% after receiving an FDA Complete Response Letter for its cancer drug ivonescimab, failing to meet overall survival statistical requirements in the HARMONi trial. However, analysts view the setback as limited since it affects only second-line treatment, with the drug's main blockbuster potential in first-line settings. Summit has 17 ongoing late-stage trials, strong financial backing from AstraZeneca, and $630 million in cash reserves to continue development.
The FDA issued a Complete Response Letter for Summit Therapeutics' ivonescimab lung cancer BLA, citing insufficient overall survival data.
Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS) stock rose
Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.
U.S. stocks were mixed on Monday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures moved in different directions.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to SMMT, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.